NCT05331300View on ClinicalTrials.gov

A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

November 27, 2024

Study Completion Date

November 27, 2024

Conditions
Pulmonary FibrosisThyroid Eye Disease
Interventions
DRUG

LASN01

Escalating single and multiple doses of LASN01

DRUG

LASN01

LASN01 will be administered intravenously

DRUG

Placebo

Escalating doses of matching placebo

DRUG

Placebo

Placebo will be administered intravenously

Trial Locations (4)

2220

Site AU05, Hurstville

3220

Site AU01, Melbourne

4006

Site AU03, Brisbane

Unknown

Site HK01, Shatin

Sponsors
All Listed Sponsors
lead

Lassen Therapeutics 1 PTY LTD

INDUSTRY

NCT05331300 - A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease | Biotech Hunter | Biotech Hunter